Morgan Stanley Vir Biotechnology, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,633,690 shares of VIR stock, worth $8.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,633,690

Previous 1,424,345 14.7%

Holding current value

$8.17 Million

Previous $9.23 Million 10.79%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$4.5 - $6.48 $942,052 - $1.36 Million	209,345 Added 14.7%	1,633,690 $8.23 Million
Q1 2025 May 15, 2025	BUY	$6.48 - $12.48 $1.95 Million - $3.75 Million	300,539 Added 26.74%	1,424,345 $9.23 Million
Q4 2024 Feb 14, 2025	SELL	$6.74 - $10.17 $762,381 - $1.15 Million	-113,113 Reduced 9.14%	1,123,806 $8.25 Million
Q3 2024 May 14, 2025	SELL	$7.26 - $10.7 $6.43 Million - $9.48 Million	-886,293 Reduced 41.74%	1,236,919 $9.26 Million
Q3 2024 Nov 14, 2024	SELL	$7.26 - $10.7 $6.43 Million - $9.48 Million	-886,293 Reduced 41.74%	1,236,919 $9.26 Million
Q2 2024 May 14, 2025	BUY	$7.63 - $12.66 $7.63 Million - $12.7 Million	999,406 Added 88.93%	2,123,212 $18.9 Million
Q2 2024 Oct 17, 2024	SELL	$7.63 - $12.66 $1.65 Million - $2.74 Million	-216,048 Reduced 9.24%	2,123,212 $18.9 Million
Q2 2024 Aug 14, 2024	SELL	$7.63 - $12.66 $1.65 Million - $2.74 Million	-216,048 Reduced 9.24%	2,123,212 $18.9 Million
Q1 2024 Oct 17, 2024	BUY	$8.6 - $11.9 $1.86 Million - $2.57 Million	216,048 Added 10.18%	2,339,260 $23.7 Million
Q1 2024 Aug 16, 2024	BUY	$8.6 - $11.9 $1.83 Million - $2.53 Million	212,981 Added 10.02%	2,339,260 $23.7 Million
Q1 2024 May 15, 2024	BUY	$8.6 - $11.9 $1.83 Million - $2.53 Million	212,981 Added 10.02%	2,339,260 $23.7 Million
Q4 2023 Aug 16, 2024	BUY	$7.76 - $10.29 $23,799 - $31,559	3,067 Added 0.14%	2,126,279 $21.4 Million
Q4 2023 Feb 13, 2024	BUY	$7.76 - $10.29 $5.73 Million - $7.6 Million	738,863 Added 53.25%	2,126,279 $21.4 Million
Q3 2023 Nov 15, 2023	BUY	$9.14 - $24.62 $6.38 Million - $17.2 Million	697,690 Added 101.15%	1,387,416 $13 Million
Q2 2023 Aug 14, 2023	BUY	$23.2 - $27.29 $2.11 Million - $2.48 Million	90,868 Added 15.17%	689,726 $16.9 Million
Q1 2023 May 15, 2023	SELL	$22.26 - $30.85 $12.9 Million - $17.9 Million	-578,970 Reduced 49.16%	598,858 $13.9 Million
Q4 2022 Feb 14, 2023	BUY	$19.96 - $28.22 $642,113 - $907,837	32,170 Added 2.81%	1,177,828 $29.8 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $1.17 Million - $2 Million	64,284 Added 5.94%	1,145,658 $22.1 Million
Q2 2022 Oct 27, 2022	BUY	$19.08 - $26.7 $9.34 Million - $13.1 Million	489,696 Added 82.76%	1,081,374 $27.5 Million
Q2 2022 Aug 15, 2022	BUY	$19.08 - $26.7 $9.34 Million - $13.1 Million	489,696 Added 82.76%	1,081,374 $27.5 Million
Q1 2022 Oct 27, 2022	SELL	$21.19 - $40.01 $10.4 Million - $19.6 Million	-489,696 Reduced 45.28%	591,678 $15.2 Million
Q1 2022 May 13, 2022	SELL	$21.19 - $40.01 $13.5 Million - $25.6 Million	-639,416 Reduced 51.94%	591,678 $15.2 Million
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $33.6 Million - $58.7 Million	1,086,524 Added 751.56%	1,231,094 $51.5 Million
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $5.05 Million - $7.88 Million	144,570 New	144,570 $6.29 Million

Others Institutions Holding VIR

# of Institutions

243

Shares Held

109M

Call Options Held

342K

Put Options Held

150K

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $663M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account